Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
View/ Open
Date
2019-04ICR Author
Author
Reck, M
Kerr, KM
Grohé, C
Manegold, C
Pavlakis, N
Paz-Ares, L
Huber, RM
Popat, S
Thatcher, N
Park, K
Hilberg, F
Barrueco, J
Kaiser, R
Type
Journal Article
Metadata
Show full item recordAbstract
A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6-9 months of first-line treatment initiation.
Collections
Subject
Lung
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Disease Progression
Indoles
Antineoplastic Combined Chemotherapy Protocols
Antibodies, Monoclonal
Disease-Free Survival
Patient Selection
Time Factors
Antibodies, Monoclonal, Humanized
Bevacizumab
Docetaxel
Research team
Thoracic Oncology
Language
eng
License start date
2019-04
Citation
Future oncology (London, England), 2019, 15 (12), pp. 1363 - 1383